Home » Newsletters » BioWorld Science

BioWorld Science

June 11, 2019

View Archived Issues

A case study exploring a novel AKT1 fusion-driven cancer

Cutting out the middleman for MSI-high diagnosis

Drivers or drifters?

Recruitment ongoing in phase II study of I-131-1095 plus enzalutamide in patients with mCRPC

FDA grants IND permission to PrimeVax for use of U.S. Army's dengue virus to treat cancer

FibroGen initiates phase III study of pamrevlumab plus chemotherapy in pancreatic cancer

Phase II results presented for PT-2385 in patients with glioblastoma

First-in-human data presented for the bispecific anti-PD-L1/CTLA-4 antibody KN-046

Safety and tolerability data from first-in-human trial of GX-G6 as potential antidiabetic

Arvinas patents new IRAK-4-targeting compounds

Innovate Biopharmaceuticals initiates first ever phase III study in celiac disease

Topline data presented from phase II study of NYX-2925 in patients with fibromyalgia

Harvard College and Eisai divulge new compounds for cancer

Hepagene Therapeutics identifies MAP3K5 inhibitors

Merck & Co. synthesizes new IDO1 inhibitors

Homology Medicines initiates phase I/II study for HMI-102 gene therapy for adults with PKU

Northwestern University presents GBA activators

FDA approves first chemoimmunotherapy regimen for patients with DLBCL

Positive topline results presented for phase II study of Gazyva in lupus nephritis

Primary objective of safety achieved in the midpoint of first-in-human study of PKX-001

AVA-004 selected as clinical candidate for development in Avacta's Affimer PD-L1 inhibitor platform

Cognitive deficits ameliorated in mouse Alzheimer's models

PPC-06 meets both coprimary endpoints in phase IIb study in plaque psoriasis

Tree SLIT-tablet against allergic rhinitis approved in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...